Eurobio Scientific FY26 H1 net income more than doubles to €4.7 million; revenue rises 4.5% to €84.5 million

By Public Technologies
  • Eurobio Scientific first-half revenue rose 4.5% to €84.5 million, while operating income climbed 45% to €8.5 million.
  • Net income more than doubled to €4.7 million; EBITDA increased 20% to €15.8 million.
  • Gross margin rate edged up 0.2 percentage points to 47.5%, and operating expenses fell to 35.1% of revenue from 37.2%.
  • Free cash flow totaled €4 million, and net debt stood at €147.4 million, including the EB Development shareholder loan.
  • CareDx’s Lab Solutions acquisition closed June 30, and EB Development proposed a tender offer at €25.30 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurobio Scientific SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241140OMX_____CNEWS_EN_GNW1001274457_en) on September 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.